4Brand R,Mahr C.Risk factors for pancreatic adenocarcinoma: are we ready for screening and surveillance? [J]. Curr Gastroenterol Rep, 2005,7(2):122-127.
5Cao LQ, Xue P, Lu HW, et al. Hematoporphyrin derivative-mediat- ed photodynamic therapy inhibits tumor growth in human cholangio- earcinoma in vitro and in vivo [J]. Hepatol Res,2009,39(12):1190- 1197.
6Pedrazzoli S,DiCarlo V,Dionigi R,et al.Standard versus extended lymphadeneetomy associated with pancreatoduodenctomy in the sur- gical treatment of adenocarcinoma of the head of the pancreas: a muhicenter, prospective,randomized study. Lymphadenectomy Study Group[J].Ann Surg, 1999,228(4):508-517.
7Fortner JG. Regional resection of cancer of the pancreas: a new sur- gical approach[J]. Surgery,1973,73(2):307-320.
8Iqbal N, Lovegrove RE, Tilney HS,et al. A comparison of pancreaticodu- odenectomy with extended pancreaticoduodenectomy: a meta-analysis of 1909 patients [J]. Eur J Surg Oncol,2009,35( 1 ) :79 -86.
9Farnell MB, Aranha GV, Ninmra Y, et al. The role of extended |ymphade- nectomy for adenocarcinoma of the head of the pancreas : strength of the evidence [ J ]. J Gastrointest Surg,2008,12 (4) : 651 - 656.
10Cao LQ, Xue P, Lu HW, et al. Hematoporphyrin derivative-mediated pho- todynamic therapy inhibits tumor growth in human cholangiocarcinoma in vitro and in vivo [J]. Hepatol Res,2009.39(12) :1190 -1197.
